Till Capital Ltd. Stock News

Instil Bio Inc (TIL) shares closed today at 0.3% above its 52 week low of $14.33, giving the company a market cap of $1B. The stock is currently down 16.0% year-to-date, down 45.6% over the past 12 months, and down 45.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 67.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 903.0% The company's stock price performance over the past 12 months lags the peer average by 48.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

DALLAS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapi

Main Study Cohort: Phase 2 clinical trial with registrational intent for patients with advanced melanoma

The clinical-stage cell therapy company reported impressive response rates for its candidate treatment against metastatic melanoma.

67% overall response rate and 19% complete response rate in 21 patients

DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL thera

The IPO market stayed busy this past week, with 11 IPOs raising $3.0 billion. New filers continued to fill the IPO pipeline, with 8 IPOs and 46 SPACs submitting initial filings.

The stock price of Instil Bio Inc (NASDAQ: TIL) increased by 32.2% in its market debut. These are the details.

DALLAS, March 18, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL thera